The US-Iran framework agreement approaches as Trump faces dual pressure from hawks and oil prices
- U.S. President Trump faces a dilemma in seeking to end the war with Iran: on one hand, he wants to reopen the Strait of Hormuz and lower domestic oil prices; on the other hand, any concession to Tehran may provoke strong opposition from the Iran hawks within his party.
- According to sources familiar with the matter, a framework agreement is in the works, which includes extending the current ceasefire and lifting Iran’s control over the crucial oil shipping lane, but postpones the nuclear issue for later negotiations. If approved, the agreement would be the most significant step toward peace since the joint U.S.-Israeli strikes on Iran, and could help ease surging energy prices.
- However, influential hawks within the Republican Party (such as Graham and Cruz) are urging Trump to “finish the job” and resume strikes to sever Iran’s nuclear capabilities. Trump countered by saying he is not in a hurry and will accept only a “great” deal.
- Leaked memorandum terms show that the proposed deal sidesteps the most intractable issues, such as the long-term status of the strait, disposal of Iran’s enriched uranium stockpile, and details of sanction relief. Critics argue that Iran could benefit more, only pledging to continue nuclear talks in the future.
- Analysts point out that Trump is attempting to secure key concessions from Iran while making only limited compromises himself, so the outcome can be portrayed as a victory. But reopening the strait merely restores the pre-war status quo and does not represent a real achievement.
- Trump faces both political and economic pressure: public approval has fallen to a new low, the mid-term elections are approaching, and high oil prices could hurt the Republican Party’s prospects. Iran, meanwhile, is demonstrating greater resilience, capable of enduring military strikes and cutting off a fifth of the world’s oil supply.
- For a president who once promised not to embroil the U.S. in unnecessary wars but has now dragged the nation into conflict, the manner in which he ends this war will determine the legacy of his second-term foreign policy.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Analyst Gu Jingci: Follow the trend and adapt flexibly
XRP Ledger adds account control feature, enabling enterprises to manage assets offline.
BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals
October 9 – Goldman Sachs pointed out that India's implementation of a 30% profit margin cap on non-scheduled anticancer drugs (link) will have limited impact on hospitals. The report states that, based on preliminary discussions with hospital chain groups, such drugs account for less than 5% of hospital revenue and 2% to 2.5% of operating profit. The report adds that hospitals can offset the losses by slightly adjusting service charges, such as administration fees. According to a government notice, an expert committee will finalize the list of drugs to be brought under regulation. Driven by the anticipated price cap, the share prices of Max Healthcare MAXE.NS, Apollo Hospitals APLH.NS, and Fortis Healthcare FOHE.NS rose by 1.6% to 2.5%. Previously, since September 30, these stocks had collectively declined by 11% to 11.5%. Year-to-date, FOHE and MAXE are down 11.7% and 14.8%, respectively, while APLH has risen by 11%. (To assist non-English speakers, Reuters provides automated translations of its reports into several other languages. Due to potential errors or missing context in automated translations, Reuters does not guarantee the accuracy of automatic translation texts and offers them solely for readers’ convenience. Reuters accepts no responsibility for any damage or loss caused by using these automated translation features.)
Adding insult to injury! Japanese electronics giant Nidec downgraded by UBS, stock price plunges over 9% and approaches an 11-month low
UBS has downgraded Nidec's rating from "Buy" to "Neutral" and lowered its target price from 2,800 yen to 2,400 yen, citing a more challenging market environment.
Crypto prices
More
